Neurotrophin-3 therapy for Charcot-Marie-Tooth disease type 1A.
Pleasure
David E
DE
Chance
Phillip F
PF
D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D002607:Charcot-Marie-Tooth Disease / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data / Q000639:trends; D004195:Disease Models, Animal; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D018993:Myelin P0 Protein / Q000378:metabolism; D009185:Myelin Proteins / Q000235:genetics*; D009186:Myelin Sheath / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D009416:Nerve Regeneration / Q000187:drug effects* / Q000235:genetics; D020933:Neurotrophin 3 / Q000494:pharmacology* / Q000627:therapeutic use; D010525:Peripheral Nerves / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D012583:Schwann Cells / Q000187:drug effects* / Q000378:metabolism
D018993:Myelin P0 Protein; D009185:Myelin Proteins; D020933:Neurotrophin 3; C073687:PMP22 protein, human